OTCMKTS:ACUR Acura Pharmaceuticals (ACUR) Stock Price, News & Analysis $0.0001 0.00 (0.00%) As of 09/22/2026 03:32 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartNews and TrendsSEC Filings About Acura Pharmaceuticals Stock (OTCMKTS:ACUR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Acura Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000150-Day Range N/A52-Week Range$0.0001▼$0.01Volume2,221 shsAverage Volume1,121 shsMarket Capitalization$6.67 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Acura Pharmaceuticals, Inc. was a specialty pharmaceutical company focused on developing and commercializing technologies intended to reduce the potential for prescription drug abuse and misuse. Its principal platform, Aversion Technology, was designed to make certain opioid formulations more difficult to manipulate for abuse through methods such as crushing, snorting, or dissolving. The company’s best-known product was Oxecta, an immediate-release oxycodone hydrochloride tablet incorporating Aversion Technology. Oxecta received approval from the U.S. Food and Drug Administration and was marketed in the United States. Acura also developed Impede Technology, which was used in Nexafed, an over-the-counter pseudoephedrine product designed to help deter the illegal extraction of pseudoephedrine for methamphetamine production. Acura’s operations and product development were primarily focused on the U.S. pharmaceutical market. The company also pursued licensing, partnering, and commercialization arrangements for its abuse-deterrent technologies and products. Publicly available information about its more recent operations, leadership, and current commercial activities is limited.AI Generated. May Contain Errors. Read More Receive ACUR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acura Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACUR Stock News HeadlinesAcura Pharmaceuticals Discloses Major SEC Filing DelaysAugust 26, 2026 | tipranks.comAcura Pharmaceuticals Secures Loan Amid Going-Concern RisksAugust 20, 2026 | tipranks.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | Porter & Company (Ad)Acura Pharmaceuticals Secures New Loan Amid Liquidity StrainJuly 24, 2026 | tipranks.comAcura Pharmaceuticals Extends Maturity of Key Secured NoteJuly 1, 2026 | theglobeandmail.comAcura Pharmaceuticals Flags Ongoing SEC Filing DelaysMay 13, 2026 | tipranks.comAcura Pharmaceuticals Secures Insider Loans Amid Liquidity StrainMay 7, 2026 | tipranks.comAcura Pharmaceuticals Inc.April 8, 2026 | barrons.comSee More Headlines ACUR Stock Analysis - Frequently Asked Questions How have ACUR shares performed this year? Acura Pharmaceuticals' stock was trading at $0.0005 on January 1st, 2026. Since then, ACUR shares have decreased by 80.0% and is now trading at $0.0001. How were Acura Pharmaceuticals' earnings last quarter? Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) issued its quarterly earnings results on Friday, February, 28th. The specialty pharmaceutical company reported $0.00 EPS for the quarter. The specialty pharmaceutical company had revenue of $1.32 million for the quarter. Does Acura Pharmaceuticals have any subsidiaries? Acura Pharmaceuticals subsidiaries include these companies: Acura Pharmaceutical Technologies Inc.. How do I buy shares of Acura Pharmaceuticals? Shares of ACUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Acura Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acura Pharmaceuticals investors own include Denali Therapeutics (DNLI), Matinas Biopharma (MTNB), Corbus Pharmaceuticals (CRBP), Fulcrum Therapeutics (FULC) and Company Calendar Last Earnings2/28/2020Today9/24/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:ACUR Previous SymbolNASDAQ:ACUR CIK786947 Webwww.acurapharm.com Phone(847) 705-7709Fax847-705-5399Employees10Year Founded1935Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares66,650,000Free Float53,186,000Market Cap$6.67 thousand OptionableNot Optionable Beta-12.37 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (OTCMKTS:ACUR) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredOn October 7th, your “safest” assets are at riskJeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...Brownstone Research | SponsoredWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...Trading Wire | SponsoredThe REAL Reason 2,000 Missiles Rained on IranTwo private meetings with U.S. Congressmen and weeks of research point to a surprising explanation for the rec...Behind the Markets | SponsoredAmazon's touch-enabled robot points to AI's next phaseAmazon wants touch-enabled robots to handle 80% of work across roughly 14 billion warehouse items a year. One ...The Oxford Club | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acura Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acura Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
